GlassScriptPhysician profile
Alexander Korchmarev
NPI 1821029042
$5,406.83
in general payments reported to CMS, 2019-2025
19 companies · $756 in 2025
The $756 reported for 2025 was more than what 77% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $778 · 2020: $586 · 2021: $970 · 2022: $805 · 2023: $690 · 2024: $822 · 2025: $756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,268.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $959.88 | 2019-2025 | Trintellix |
| Lundbeck LLC | $645.69 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $631.66 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $590.61 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $518.82 | 2022-2025 | Caplyta |
| Allergan, INC. | $431.46 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $295.54 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $264.47 | 2022-2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $185.06 | 2022-2023 | Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $178.55 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $153.58 | 2025 | Cobenfy |
| Alkermes, INC. | $148.88 | 2023-2024 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $142.62 | 2019-2025 | Fanapt |
| Bausch Health US, LLC | $73.20 | 2020-2021 | |
| Axsome Therapeutics, INC. | $67.11 | 2022-2023 | Auvelity |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $54.19 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $22.25 | 2025 | Qelbree |
| Arbor Pharmaceuticals, INC. | $21.82 | 2020 | |
| Neuronetics, INC. | $21.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Korchmarev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.